Synmosa Biopharma Cash Flow Quality Index
Synmosa Biopharma cash flow quality index. Synmosa Biopharma (4114) has a Cash Flow Quality Index of 0.98x as of December 2025. Operating cash flow of NT$185.72 Million is below net income of NT$189.22 Million, suggesting accrual-heavy earnings not yet converted to cash. See Synmosa Biopharma financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Synmosa Biopharma (2015–2025)
Cash flow quality index of Synmosa Biopharma from 2015 to 2025. Historical Cash Flow Quality Index for Synmosa Biopharma across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Synmosa Biopharma (4114) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Synmosa Biopharma Cash Flow Quality Index by Year (2015–2025)
Synmosa Biopharma cash flow quality index by year from 2015 to 2025. Year-by-year earnings quality comparison for Synmosa Biopharma. For the full cash flow conversion analysis, see Synmosa Biopharma operating cash flow efficiency.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.50x | NT$411.57 Million | NT$821.85 Million | ▼ -56.1% |
| 2024 | 1.14x | NT$780.62 Million | NT$684.68 Million | ▲ +24.2% |
| 2023 | 0.92x | NT$511.93 Million | NT$557.82 Million | ▲ +16.4% |
| 2022 | 0.79x | NT$630.25 Million | NT$799.09 Million | ▼ -46.1% |
| 2021 | 1.46x | NT$444.29 Million | NT$303.86 Million | ▲ +266.8% |
| 2020 | 0.40x | NT$254.40 Million | NT$638.11 Million | ▲ +141.8% |
| 2019 | -0.95x | NT$-44.88 Million | NT$47.09 Million | ▼ -2667.5% |
| 2018 | 0.04x | NT$16.00 Million | NT$430.90 Million | ▲ +103.4% |
| 2017 | -1.11x | NT$-5.19 Million | NT$4.69 Million | ▼ -178.1% |
| 2016 | 1.42x | NT$236.48 Million | NT$166.65 Million | ▲ +89.6% |
| 2015 | 0.75x | NT$23.60 Million | NT$31.54 Million | — |